Differences in the levels of TSH-binding inhibitor immunoglobulins in goitrous and agoitrous autoimmune thyroiditis after twelve months of L-thyroxine therapy

OBJECTIVE The aims were to study the prevalence of TSH binding inhibitor immunoglobulins (TBII) in newly diagnosed patients with autoimmune hypothyroidism, to determine if clinical and biochemical parameters in these patients differed, and to study the course of these antibodies after 12 months of L-thyroxine (LT4) therapy, SUBJECTS AND DESIGN In a prospective study, 111 consecutive patients with newly diagnosed autoimmune hypothyroidism were enrolled. Patients were divided into groups according to the presence or absence of a goitre and TBII levels. Clinical and biochemical differences in these patients were analysed. Patients were then treated with L-thyroxine (LT4) for 12months and changes in their TBII monitored. MEASUREMENTS Free T4 and TSH levels were measured at baseline and then 6-weekly during the titration of LT4 doses, Once TSH levels had normalized, these measurements were performed 3 monthly, TBII levels were measured in patients at baseline and 12months, Thyroid stimulating blocking antibody (TSBAb) levels were measured 12-18 months after initiation of LT4 therapy, RESULTS Twenty patients were TBII-positive, 10 goitrous and 10 agoitrous, Agoitrous TBII-positive patients were found to have similar characteristics: these included TBII levels > 100U/I, potent thyroid stimulating blocking antibody (TSBAb) activity and a tendency for TBII levels to remain unchanged or to rise after LT4 therapy. The degree of hypothyroidism seen in these cases was significantly greater than in all other groups, In contrast, goitrous TBII-positive patients were heterogenous, most did not have significant TSBAb activity and TBII disappeared in 5 out of 10 cases after a year of LT4 treatment. While Tall disappeared in 6 of the 20 patients after a year, remission of hypothyroidism occurred in only 3 cases, CONCLUSIONS The degree of hypothyroidism in agoitrous TSH-binding inhibitor immunoglobulins-positive patients appears to be more severe than that seen in other forms of AIT, The differences in thyroid stimulating blocking antiboby activity and response to LT4 therapy in agoitrous and goitrous autoimmune thyroiditis suggest that the TSH-binding inhibitor immunoglobulins in these patients are fundamentally different. The disappearance of TSH-binding inhibitor immunoglobulins in hypothyroid patients was not accompanied by the reversal of hypothyroidism in 50% of patients.